# COST-EFFECTIVENESS OF EARLY CASE DETECTION FOR VISCERAL LEISHMANIASIS IN NEPAL



### Mr. SUBHASH POKHREL

A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in Health Economics Department of Economics Faculty of Economics Chulalongkorn University Academic Year 1999 ISBN:974-334-779-8

110274622

Accepted by the Faculty of Economics, Chulalongkorn University in Partial Fulfillment of the Requirements for Master's Degree

(Associate Professor Suthiphand Chirathivat, PhD)

Thesis Committee:

& hidrahis ... Chairperson

(Assistant Professor Kaemthong Indaratna, PhD)

(Associate Professor Isra Sarntisart, PhD)

P. Kam Z. Thesis Co-advisor

(Professor Pirom Kamol-ratanakul, MD)

Manisni Puntulap Member (Associate Professor Manisri Puntularp)

P. Jenodachab Member (Phitsanes Jessadachatr, PhD)

# 421441

#### # 4285749829 : MAJOR HEALTH ECONOMICS KEYWORDS : COST-EFFECTIVENESS/ EARLY CASE DETECTION/ VISCERAL LEISHMANIASIS/ NEPAL SUBHASH POKHREL: COST-EFFECTIVENESS OF EARLY CASE DETECTION FOR VISCERAL LEISHMANIASIS IN NEPAL. THESIS ADVISOR: ASSOC. PROF. ISRA SARNTISART, PhD., THESIS CO-ADVISOR: PROF. PIROM KAMOL\_RATANAKUL, MD., 83 pp. ISBN: 974-334-779-8

In Nepal, approximately 5.5 million people are at risk of infection from visceral leishmaniasis (VL), a disease if untreated is lethal in 100 per cent of cases with developed signs and symptoms. This study assessed the cost-effectiveness of early case detection for VL in Siraha district of Nepal. Two kinds of alternative programs were studied: 1) outreach case detection, which used k39 dipstick as diagnostic test and 2) health facility based detection, which used bone marrow aspiration for detection of VL. The evaluation period was 1998-99, and the study was carried out from providers' and patients' viewpoint.

A cost-effectiveness analysis (CEA) model was used to assess the efficiency of these two programs. Data on providers' costs were collected from Siraha District Hospital and Kala-azar Project, which respectively represented health facility based and outreach detection program. Patients' costs were assessed by interviewing a sample of 50 VL cases detected by these two programs in the year 1998-99. Outcomes were expressed in terms of number of cases detected and with some assumptions, this was converted to number of deaths averted.

The study shows that outreach program detected 40.9 cases per 100,000 population at risk while health facility based program detected 34.1 cases. The cost per case detected in outreach program was USD 124 and in health facility based program it was USD 191. The outreach and health facility based program incurred USD 131 and 200 respectively for an aversion of one death. Median costs to patients in outreach program was found to be USD 25 while it was six times higher in health facility based program (USD 146), of which indirect costs due to absence from work accounted for more than half in both programs.

In conclusion, the results indicate that it is worthwhile to invest in outreach program for early VL case detection from both providers' and patients' perspectives. Since outreach program can not replace the existing health facility based program under the current health care delivery system, it is recommended that outreach program be added to the health facility. In such a case, it would help to reduce patients' burden of disease substantially and the health care delivery could also be more efficient and equitable.

ภาควิชา	ECONOMICS	ลายมือซื่อนิสิต	nl
สาขาวิชา		ลายมือซื่ออาจารย์ที่ปรึกษา	
ปีการศึกษา	1999	ลายมือชื่ออาจารย์ที่ปรึกษาร่วม <i>P. Kam</i>	Jez-

#### ACKNOWLEDGEMENT

I would like to express my profound gratitude to Associate Professor Isra Sarntisart, my thesis advisor, and Professor Pirom Kamol-ratanakul, my thesis co-advisor, without whose kind support, timely advice and continuos encouragement, this report would not have been prepared. I am also deeply indebted to Assistant Professor Kaemthong Indaratna, Associate Professor Manisri Puntularp and Dr Phitsanes Jessadachatr for their sincere comments. I sincerely acknowledge the support from all faculty members at MSc in Health Economics Program, Chulalongkorn University. I am also thankful to Associate Professor Waranya Patarasuk, Dr Mahmud Khan, Dr Chev Kidson and Dr Youngyuth Chaiyapong for their noteworthy comments.

I would like to take this opportunity to thank Professor Madan P. Upadhyay and Dr Anand B. Joshi, whose continuos encouragement directed me to study Health Economics and do this research. The support I received from my director Professor Shashank Koirala, and other faculty members, and colleagues at my institution was really amazing.

The UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) supported me to study MSc in Health Economics at Chulalongkorn University and also provided me with a research grant to conduct this study. My sincere appreciation goes to Mr. Steven Wayling and Mrs. Janet Richard at TDR, who have been so cooperative during this time.

The fifty kala-azar cases whom I interviewed for this study deserve special thanks. Thanks are also due to the Kala-azar Project and its staff, Dr K.P. Singh, Medical Superintendent at Siraha Hospital, Mr Satyanarayan, Mr Dwarik and Mr Yadav at Siraha hospital. I am also thankful to my colleagues at MSc Health Economics 1999 batch. Without the tireless support from Ms. Nagmsiri and Mrs. Kingthong, the staff at MSc Program, my working on this project would not have been so enjoyable. My friends Devendra and Ram helped me a lot in this project.

Finally, I can not remain without acknowledging my parents, who missed their eldest son all the time while I was away from home for the study, and extended their blessings, love and support to me. The wonderful support I received from my bother Kamal, and wife Indu were milestones in completing this assignment.

Subhash Pokhrel April, 2000

## TABLE OF CONTENTS

### Page

Abstract	iii
Acknowledgement	iv
Contents	v
List of Tables	viii
List of Figures	ix
List of Acronyms	x

Chapter I	Introduction	1
	1.1 Background	1
	1.2 Rationale	3
	1.3 Research Question	6
	1.4 Research Objectives	6
	1.5 Scope of the Study	6
Chapter II	Literature Review	7
	2.1 Magnitude/Burden of Disease	7
	2.2 Current practice and its implication on early detection	8
	2.2.1 VL Control Activities in Nepal	9
	2.3 Importance of Early Case Detection	10
	2.4 Economic Evaluation of Case Detection: A Review of Past Studies.	12
	2.5 Measure of Effectiveness in Reported Studies	14
	2.6 Other Approaches in Defining Effectiveness	16

Chapter III	Research Methodology	18
	3.1 Research Design	18
	3.2 Definition of Alternatives and their Effectiveness	18
	3.3 Viewpoint for the Analysis	22
	3.4 Conceptual Framework	23
	3.5 Selection of Research Setting	25
	3.6 Study Population, Sampling and Inclusion Criteria	25
	3.7 Study Instruments	26
	3.8 Validity and Reliability	27
	3.9 Data collection and Analysis	27
	3.9.1 Costs Data	27
	3.9.2 Considerations of Costs of False Negatives and False Positives	28
	3.10 Outcome Measurement and Valuation	29
	3.11 Translation of Effectiveness into Monetary Term	30
	3.12 Cost-Effectiveness Analysis	32
Chapter IV	Results and Analysis.	33
	4.1 Results of k39 Dipstick Tests' Performance for Case Detection.	33
	4.2 Provider's Costs for Case Detection and Treatment	34
	4.2.1 Costs to Health Facility Based Case Detection	34 39
	4.3 Patient's Costs for VL Case Detection and Treatment	43
	4.3.1 Summary Statistics of VL Cases Interviewed	43
	4.3.2 Costs to Patients	44
	4.4 Effectiveness of the Programs	50
	4.5 Cost Effectiveness Analysis	51
	4.6 Translation of Effectiveness into Monetary Terms	52
	4.7 Sensitivity Analysis	54

Chapter V	Discussion and Conclusion	56
	5.1 Discussions	56
	5.2 Conclusion	62
	5.3 Policy Implications.	63
	5.4 Suggestions for Further Research	64
	5.5 Limitations of the Study	65
References		66
Appendices		
Appendi	x A: Questionnaire for Patients Survey	70
Appendi	x B: Background Information on Nepal	72
Appendi	x C: Map of Nepal	75
Appendi	x D: Staffing Costs	76
Appendi	x E: Capital Costs	77
Appendi	x F: Material Costs	78
Appendi	x G: Calculation of Unit Costs for Investigations	79
Appendi	x H: Calculation of Drug Costs to Providers and Patients	80
Appendi	x I: Summary Statistics of VL Case Interviewed	81
Appendi	x J: Patients Costs	82
Curriculum V	/itae	83

#### LIST OF TABLES

Table		Page
1.1	Profile of Visceral Leishmaniasis in Nepal from 1980-98	3
2.1	Examples of Effectiveness Measures Used in Cost Effectiveness Analysis	15
3.1	Summary of Data Requirement and their Sources	26
3.2	Identification, Measurement and Valuation of Costs	27
3.3	Criteria for Allocation of Overhead Costs	28
4.1	Performance of k39 Dipstick Screening Test	33
4.2	Staffing Costs of Health Facility Based Case Detection Program	35
4.3	Capital Costs of Hospital Based Case Detection Program	37
4.4	Material Costs to Health Facility Based Detection Program	38
4.5	Calculation of Total Costs to Outreach Case Detection Program	40
4.6	Calculation of Total Costs to Outreach Case Detection Program with Three Different Unit Costs of Ingredients	42
4.7	Summary Statistics of VL Cases Interviewed	43
4.8	Median Costs to Patients due to VL by Different Headings Expressed in terms of Days of Earnings	46
4.9	Distribution of Total Costs by Income Level	48
4.10	Distribution of Total Costs by Sex	48
4.11	Distribution of Total Costs by Time Lag between Infection and Seeking Health Care	49
4.12	Cost Effectiveness Ratio of Two Alternative Programs for VL Case Detection	51
4.13	Cost Effectiveness Ratio of Two Alternative Programs for VL Case Detection, after excluding the capital items	52
4.14	Value of Potential Life Years Saved by VL Case Detection Program	53
4.15	Sensitivity Analysis with Discount Rate	54
4.16	Sensitivity Analysis with Probability of Survival	55

#### LIST OF FIGURES

Figure		Page
2.1	A Model for Early Case Detection	11
3.1	Outcome Spectrum for the Case Detection Program	21
3.2	Conceptual Framework for the Study	24

#### LIST OF ACRONYMS

CBA		:	Cost-benefit analysis
CEA		:	Cost-effectiveness analysis
CUA		£.	Cost-utility analysis
DAT		:	Direct Agglutination Test
EDCD		p	Epidemiology and Disease Control Division
HMG		ŝ,	His Majesty's Government
ICER	•	ā,	Incremental cost-effectiveness ratio
IRR		÷	Internal rate of return
МОН		r.	Ministry of Health
NB		•	Net benefit
NPR		1	Nepalese Rupees
NPV		÷	Net present value
Rs.		ł	Rupees (Nepalese)
TDR		:	UNDP/World Bank/WHO Special Program for Research and
			Training in Tropical Diseases
USD		ť	United States Dollars
VBDRTC		:	Vector Borne Disease Research and Training Center
VL		:	Visceral Leishmaniasis